JLE

Hépato-Gastro & Oncologie Digestive

MENU

Circulating tumor DNA in the CRICKET study, a biomarker to know Volume 26, issue 7, Septembre 2019

  • [1] Mauri G., Pizzutilo E.G., Amatu A. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treat Rev. 2019;73:41-53.
  • [2] Di Fiore F., Sesboüé R., Michel P., Sabourin J.C., Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer. 2010;103:1765-1772. 12
  • [3] Misale S., Di Nicolantonio F., Sartore-Bianchi A., Siena S., Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer : from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269-1280. 11
  • [4] Lièvre A., Bachet J.-B., Le Corre D. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995. 8
  • [5] Di Fiore F., Blanchard F., Charbonnier F. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166-1169. 8
  • [6] Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-2648. 6
  • [7] Diaz L.A. Jr., Williams R.T., Wu J. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537-540. 7404
  • [8] Misale S., Yaeger R., Hobor S. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536. 7404
  • [9] Bettegowda C., Sausen M., Leary R.J. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24. 224
  • [10] Corcoran R.B., Chabner B.A. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med. 2018;379:1754-1765. 18
  • [11] Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019 Feb 22. doi : 10.1038/s41571-019r-r0187-3.
  • [12] Santini D., Vincenzi B., Addeo R. Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? Ann Oncol. 2012;23:2313-2318. 9
  • [13] Siravegna G., Mussolin B., Buscarino M. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795-801. 7
  • [14] Van Emburgh B.O., Arena S., Siravegna G. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016;7:13665.
  • [15] Grothey A., Van Cutsem E., Sobrero A. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-312. 9863
  • [16] Li J., Qin S., Xu R. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619-629. 6
  • [17] Mayer R.J., Van Cutsem E., Falcone A. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909-1919. 20
  • [18] Xu J., Kim T.W., Shen L. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer : The TERRA Study. J Clin Oncol. 2018;36:350-358. 4
  • [19] Sartore-Bianchi A., Trusolino L., Martino C. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738-746. 6
  • [20] Meric-Bernstam F., Hurwitz H., Raghav K.P.S. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518-530. 4
  • [21] Le D.T., Durham J.N., Smith K.N. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-413. 6349
  • [22] Overman M.J., Lonardi S., Wong K.Y.M. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36:773-779. 8
  • [23] Ardini E., Bosotti R., Borgia A.L. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014;8:1495-1507. 8
  • [24] Sartore-Bianchi A., Ardini E., Bosotti R. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2016;108. 1